LON:PRM Proteome Sciences (PRM) Share Price, News & Analysis GBX 3 -0.09 (-2.91%) As of 05/9/2025 12:12 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Proteome Sciences Stock (LON:PRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Proteome Sciences alerts:Sign Up Key Stats Today's Range 3▼ 350-Day Range 2.50▼ 4.5052-Week Range 2.22▼ 5.40Volume130,450 shsAverage Volume226,214 shsMarket Capitalization£8.86 millionP/E RatioN/ADividend Yield6.17%Price TargetN/AConsensus RatingN/A Company OverviewProteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.Read More… Receive PRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteome Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PRM Stock News HeadlinesProteome Sciences Full Year 2024 Earnings: UK£0.011 loss per share (vs UK£0.008 loss in FY 2023)April 12, 2025 | finance.yahoo.comProteome Sciences Secures £1 Million Loan to Boost Capacity Amid Market GrowthDecember 23, 2024 | tipranks.comThis robot is coming to 65 million Americans … this year.The Robotics Revolution has arrived. And not surprisingly, Nvidia is leading the way. Nvidia CEO Jensen Huang recently laid out their vision for the future of robotics.May 10, 2025 | Weiss Ratings (Ad)Proteomics and AI unite for a new era in medicine and health careDecember 12, 2024 | msn.comNanoparticle approach enhances detection of low-abundance proteins in blood plasmaNovember 9, 2024 | msn.comProteome Sciences plc (PRM.L)November 6, 2024 | finance.yahoo.comBruker Announces One-Hundred Dollar, Deep, High-Accuracy Plasma Proteome; Advances Glycoproteomics and MetaproteomicsOctober 21, 2024 | tmcnet.comSix proteins may hold key to diagnosing early-onset preeclampsiaOctober 16, 2024 | msn.comSee More Headlines PRM Stock Analysis - Frequently Asked Questions How have PRM shares performed this year? Proteome Sciences' stock was trading at GBX 3.40 on January 1st, 2025. Since then, PRM shares have decreased by 11.8% and is now trading at GBX 3. View the best growth stocks for 2025 here. How were Proteome Sciences' earnings last quarter? Proteome Sciences plc (LON:PRM) released its quarterly earnings data on Thursday, April, 10th. The company reported ($1.15) earnings per share for the quarter. Proteome Sciences had a negative net margin of 0.04% and a negative trailing twelve-month return on equity of 0.01%. How do I buy shares of Proteome Sciences? Shares of PRM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Proteome Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Proteome Sciences investors own include Lloyds Banking Group (LLOY), Petrofac (PFC), ValiRx (VAL), boohoo group (BOO), Intel (INTC), Mondi (MNDI) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings4/10/2025Today5/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryChemicals Current SymbolLON:PRM CIKN/A Webwww.proteomics.com Phone+44-20-70432116FaxN/AEmployees240Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-4,078,846.53 Net Margins-0.04% Pretax MarginN/A Return on Equity-0.01% Return on Assets-19.25% Debt Debt-to-Equity Ratio-258.66 Current Ratio0.20 Quick Ratio0.37 Sales & Book Value Annual Sales£10.88 billion Price / Sales0.00 Cash FlowGBX 0.80 per share Price / Cash Flow3.73 Book ValueGBX (1.78) per share Price / Book-1.68Miscellaneous Outstanding Shares295,167,274Free FloatN/AMarket Cap£8.86 million OptionableNot Optionable Beta0.07 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (LON:PRM) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Remember when they said crypto would never go mainstream? Well, something remarkable has happened… Blac...Crypto 101 Media | SponsoredTrump’s Secret WeaponWall Street is nervous. Billionaires are shifting assets. And everyday investors? Most are completely unprepa...American Alternative | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | SponsoredNew Global Crisis Threatens U.S. RetirementsA new global crisis has just detonated… fueled by escalating trade wars and aggressive moves by evil foreign p...Premier Gold Co | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteome Sciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteome Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.